Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03725332
Other study ID # 44929
Secondary ID MAT-2017C2-7842
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 13, 2019
Est. completion date April 2024

Study information

Verified date December 2023
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Perinatal opioid use disorder (OUD) is a major health concern in the U.S. with significant impact on mothers, infants, and communities. Investigators at the University of Kentucky/UK HealthCare (UK) have developed a comprehensive clinical care model for perinatal OUD (known as UK-PATHways) that has demonstrated success in maternal and neonatal outcomes. The overreaching goals of the proposed project are to: 1) expand the reach of this successful clinical program, 2) to reduce the impact of perinatal OUD in underserved rural areas of our state, and 3) to compare the relative effectiveness methods of delivery active elements of the PATHways program for rural implementation (local group-support vs. UK nurse/counselor telemedicine)


Description:

The UK-PATHways program preliminary successes during the first three years are clear: enrolled mothers (n>200) have reduced relapse, increased treatment compliance, and improved neonatal outcomes when compared to non-enrolled OUD mothers. However, at this time,UK-PATHways is only available at our main healthcare campus in Lexington, KY. Many eligible patients reside great distances from our clinical home and some current patients travel hours to access this valuable resource. While Medication Assisted Therapy (MAT) has become increasingly available in our region, many of the components of the UK-PATHways program are not readily accessible in rural Central and Eastern Kentucky and the quality of programming with MAT treatment is not standardized in these locations. Furthermore, rural patients continue to face challenges related to stigma of their OUD and transportation difficulties if they desire more comprehensive services. The proposed study will evaluate the introduction of essential components of the UK-PATHways program into rural communities, and identify the optimal intervention strategies for expansion of services and to improve the treatment of OUD for rural patients. Specific aims include the following: Aim 1) Conduct a randomized cluster trial using a 'hub and spoke' study design, comparing two delivery modes (local GROUP care vs TELEMEDICINE) for the delivery of a PATHways based patient education curriculum at participating rural regional sites. Each regional site will be randomized to support one of two study arms: 1) Prenatal group care led by a Perinatal Nurse Facilitator and Peer Support Specialist (GROUP arm); or, 2) Telemedicine consultation with substance abuse counselors, perinatal nurse educators, and/or Peer Health Specialists based at the 'hub' site (TELEMEDICINE arm); and Aim 2) Evaluate the relative effectiveness of each study arm on primary and secondary maternal and neonatal outcomes as compared to the established PATHways program (UK-PATHways: Hub) at the University of Kentucky.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 269
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Pregnant women at 6 to 32 weeks' gestational age - History of Opioid Use Disorder - Receiving Medication Assisted Therapy (buprenorphine products or methadone) - Obtaining prenatal care at one of eleven study sites located throughout Central and Eastern Kentucky Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Telemedicine
Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance abuse counselors, perinatal nurse educators, and/or Peer Health Specialists. Consultations will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
Group Care
Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator and community-based peer support specialist. Small group care meetings will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1)Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.

Locations

Country Name City State
United States Karen's Place Maternity Center Ashland Kentucky
United States The Medical Center Bowling Green Kentucky
United States Grace Health Women's Care Corbin Kentucky
United States University of Kentucky Women's Health OB-GYN Georgetown Kentucky
United States Primary Care Centers of Eastern Kentucky Hazard Kentucky
United States OB/GYN & Women's Health University of Louisville Louisville Kentucky
United States ARH Women's and Family Health Center - Middlesboro Middlesboro Kentucky
United States University of Kentucky Morehead Women's Healthcare Morehead Kentucky
United States Frontier Behavioral Health Centers Prestonsburg Kentucky
United States ARH Women's and Family Health Center - Tug Valley S. Williamson Kentucky

Sponsors (2)

Lead Sponsor Collaborator
Wendy F Hansen Patient-Centered Outcomes Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in employment status Participants will be asked about employment status during their intake visit, at 28 weeks gestational age, 3 months postpartum and 6 months postpartum (combined total time of observation is up to 60 weeks). Participants will answer "yes" or "no" regarding their employment status. Data will be presented as the change in employment status between groups. Up to 60 weeks
Other Change in household size Participants will be asked to indicate the total number of people sharing their living space during the intake visit, and 6 months postpartum (combined total time of observation is up to 38 weeks). Data will be presented as the change in dwelling occupancy over time compared between groups. up to 38 weeks
Other Acceptance of long term contraception Participants will be offered long acting reversible contraception at time of delivery (up to 34 weeks into the study assuming delivery at 40 weeks gestation). Data will be presented as the number of participants per group accepting long term contraception. Up to 34 weeks
Primary Incidence of medication requiring neonatal abstinence syndrome (NAS) Medical records will be reviewed at 3 months post-partum visit for treatment for NAS. Diagnosis of NAS will be made within 10 days of birth and treatment started based on standard of care. Data will be presented as the percent of infants born requiring therapy in each group. up to 10 days postpartum
Secondary Change in cigarette dependency Participants will complete the Fagerstrom Test For Cigarette Dependence during their intake visit, at 28 weeks gestational age, 3 months postpartum and 6 months postpartum (combined total time of observation is up to 60 weeks). The survey instrument asks seven questions related to cigarette dependency. Responses will be scored on a scale of zero to 3 and totaled. Any score greater than 8 is considered high dependency, a score of 5-7 is considered moderately dependent, 3-4 is low to moderate dependence and 1-2 is low dependence. Data will be presented as the change in cigarette dependency over time compared between groups. Up to 60 weeks
Secondary Change in maternal anxiety over time Participants will complete the Generalized Anxiety Disorder 7-Item scale during their intake visit, at 28 weeks gestational age, 3 months postpartum and 6 months postpartum (combined total time of observation is up to 60 weeks). The survey consisted of 8 questions scored between zero (no anxiety) and 3 (daily anxiety) were a total score of 1-4 indicates minimal anxiety and a score of 15-21 indicates severe anxiety. Data will be presented as the change in anxiety over time compared between groups. Up to 60 weeks
Secondary Change in maternal depression over time Participants will complete the Edinburgh Depression Scale during their intake visit, at 28 weeks gestational age, 3 months postpartum and 6 months postpartum (combined total time of observation is up to 60 weeks). The survey consisted of 10 questions scored between 1 (no depression) and 4 (daily depression) were a total score of 1-8 is normal, a score is 9-10 is at risk for depression and a score of 11 or more indicates severe depression. Data will be presented as the change in depression over time compared between groups. Up to 60 weeks
Secondary Change in quality of life WHO-Quality of Life Survey (WHOQoL) will be administered to patients at 28 weeks gestation, 3 and 6 months postpartum ( total time frame up to 38 weeks). WHOQoL is a 26 question self administered survey. Each question falls within 1 of 4 "domains": physical health, psychological health, social relationships, environment. The four domains are added up to create 4 raw domain scores and means are calculated. These are transformed into transformed scores of "0 - 100". Higher scores indicate higher perceived quality of life in that particular domain. Data will be presented as the change in depression over time compared between groups up to 38 weeks
Secondary Opioid Use Disorder Participants will complete a survey to assess their opioid dependency during their intake visit (typically between 6-28 weeks gestation). The survey asks 11 questions related to opioid use in a yes/no format. 2-3 "yes" answers indicates mild opioid use, "yes" to 4-5 questions indicates moderate use and "yes" to 6 or more questions indicates severe dependency. Data will be presented as the mean +/-standard error of the dependency scores per group. Intake visit (between 6-28 weeks gestation)
Secondary Incidence of hospitalization for opioid related issues during the study period Participants will be surveyed for hospitalizations during the study but not related to participation in the study at 28 weeks gestation and 3 and 6 months postpartum (total time frame up to 38 weeks). They will be asked a series of "yes" or "no" questions. Data will presented as the total number of "yes" answers per group over the course of the study. up to 38 weeks
Secondary Change in physical condition of infant post delivery Infant physical condition at birth with be assessed using the Apgar scale at 1 minute, 5 minutes and 10 minutes after birth. The Apgar scale consists of 5 criteria scored 0-2. Scores are combined for a total score of between 0-10 were 10 is a very healthy infant and 0 is an infant requiring immediate intensive medical care. Data will be presented as the change in Apgar score over time compared between groups. Up to ten minutes
Secondary Incidence of pediatric emergency room (ER) visits A medical record review will take place to determine if any ER visits took place in the first 6 months of the infants life. Data will be presented as the total number of ER visits compared between groups six months
Secondary Adherence to a vaccine schedule A medical record review will take place to determine if the infant's vaccine schedule was maintained in the first 6 months of the infants life. Data will be presented as the percent of infants in each group considered compliant and compared between groups. six months
Secondary Adherence to a pediatric visit schedule A medical record review will take place to determine if the infant's pediatric visit schedule was maintained in the first 6 months of the infants life. Data will be presented as the percent of infants in each group considered compliant and compared between groups. six months
Secondary Infant motor development At three months of age, infant mom/caregivers will be asked to complete the Ages & Stages Questionnaires®, Third Edition (ASQ®-3), a developmental screening tool designed for use by early educators and health care professionals. The survey collects milestones in infants in five domains; communication, gross motor, fine motor, problem-solving, and personal/social. It takes just 10-15 minutes for parents to complete and 2-3 minutes for professionals to score and highlights results that fall in a "monitoring zone", to make it easier to keep track of children at risk. The Ages and Stages 3 month survey instrument is 38 items filled out by the caregiver and scored by the clinic staff. Scores are calculated at 0, 5, or 10 per question, and lower scores are interpreted to support further professional assessment concerning the infant's development. Scale scores will be presented as the mean +/- standard error per group compared between groups. 3 months postpartum
Secondary Infant motor development At six months of age, infant mom/caregivers will be asked to complete the Ages & Stages Questionnaire, Third Edition to provide a snapshot need to catch delays and celebrate milestones. The survey collects milestones in infants in five domains; communication, gross motor, fine motor, problem-solving, and personal/social. It takes just 10-15 minutes for parents to complete and 2-3 minutes for professionals to score and highlights results that fall in a "monitoring zone", to make it easier to keep track of children at risk. The Ages and Stages 6 month survey instrument is 38 items filled out by the infants caregiver and scored by the clinic staff. Scores are calculated at 0, 5, or 10 per question, and lower scores are interpreted to support further professional assessment concerning the infant's development. Scale scores will be presented as the mean +/- standard error per group compared between groups. 6 months postpartum
Secondary Incidence of opioid relapse A medical record review and patient interview at each visit will be used to determine the number of participants in each group that began using illicit substances after a period of sobriety. Data will be collected at the intake visit, admission for delivery, and 3 and 6 months postpartum (up to 60 weeks). Data will be presented as the total count of relapse events in each group over the course of the study compared between groups. Up to 60 weeks
Secondary Incidence of opioid overdose A medical record review and patient interview at each visit will be used to determine the number of participants in each group that experienced an opioid overdose. Data will be collected at the intake visit, admission for delivery, and 3 and 6 months postpartum (up to 60 weeks). Data will be presented as the total count of overdose events in each group over the course of the study compared between groups. Up to 60 weeks
See also
  Status Clinical Trial Phase
Completed NCT01965704 - Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Phase 2
Completed NCT03890562 - Assessing the Effects of Auricular Acupressure on Newborns With NAS N/A
Completed NCT01958476 - Improving Outcomes in Neonatal Abstinence Syndrome Phase 3
Active, not recruiting NCT01734551 - NAS Treatment - Opiate Versus Non-Opiate Phase 4
Completed NCT00496951 - Vagal Tone and Neonatal Abstinence Syndrome N/A
Completed NCT02851303 - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Phase 4
Recruiting NCT05226624 - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program N/A
Completed NCT03670160 - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Phase 2
Not yet recruiting NCT04611659 - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine N/A
Completed NCT01452789 - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Phase 3
Completed NCT04588519 - tAN to Mitigate Withdrawal Behaviors in Neonates N/A
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT02801331 - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome N/A
Terminated NCT03246243 - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed NCT03567603 - Sound Processing Changes in Babies With Opioid Exposure
Recruiting NCT06303986 - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Recruiting NCT04983563 - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units N/A
Completed NCT04298853 - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Phase 4
Completed NCT02182973 - Donor Human Milk in Neonatal Abstinence Syndrome
Completed NCT02810782 - How to Treat Opiate Withdrawal in Neonates Phase 3